---
trial_id: 1750
discovery_date: 2022-09-25 17:44:25.485599
date: 2022-09-25 17:44:25.485599
title: "A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PR..."
summary: |
  <p>EudraCT Number: 2019-003919-53<br />Sponsor Protocol Number: GN41791<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-12-17<br />Medical condition: Primary Progressive multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/IT">IT</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003919-53'
published_date: NaT
trial_source: 
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2019-003919-53<br />Sponsor Protocol Number: GN41791<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-12-17<br />Medical condition: Primary Progressive multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/IT">IT</a> (Ongoing)</p>